Compare Ascendis Pharma A/S (ASND) vs Canadian National Railway Co. (CNI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Canadian National Railway Co. — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Canadian National Railway Co. trades at $124.96 (market cap $75.28B). The key difference: Canadian National Railway Co. is far larger — about 4.2× Ascendis Pharma A/S's market cap, and Canadian National Railway Co. pays a 2.07% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | CNI | |
|---|---|---|
Market Cap | $17.74B | $75.28B |
Sector | Health | Industrials |
52-Week High | $277.18 | $124.40 |
52-Week Low | $163.32 | $90.91 |
Enterprise Value | $18.11B | $90.74B |
Dividend Yield | — | 2.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
CNI trades at $124.40, up 0.05% with a bullish technical outlook. The company reported Q1 2026 EPS of $1.31, meeting expectations, and maintains strong profitability with a 27.23% net margin. Recent news highlights record propane shipments and a new potash transport agreement with BHP, signaling operational strength. Analyst consensus is a Buy with a $143.71 price target, implying 15.5% upside from current levels.
The stock presents a solid long-term opportunity driven by operational efficiency and strategic growth initiatives, though elevated valuation multiples and rising debt levels warrant caution. Near-term performance hinges on Q2 2026 earnings due July 24, 2026, with market sentiment leaning positive amid sustainable dividend payments and institutional support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Canadian National Railway Co.
Canadian National's railway spans Canada from coast to coast and extends through Chicago to the Gulf of Mexico. In 2019, CN delivered almost 6 million carloads over its 19,600 miles of track. CN generated roughly CAD 14 billion in total revenue by hauling intermodal containers (25% of consolidated revenue), petroleum and chemicals (21%), grain and fertilizers (16%), forest products (12%), metals and mining (11%), automotive shipments (6%), and coal (4%). Other items constitute the remaining revenue.
Read more on CNI →
